

1/8




Fig. 1A




Fig. 1B





Fig. 2

3/8



	Compound 25	BGJ398
IC50 [nM]	3.055e-008	3.234e-007

Fig. 3

4/8




Fig. 4





Fig. 5


6/8



A line graph depicting the antitumor effect of Compound 25 (100 mg/kg PO BID) ($\square$), Compound 25 (300 mg/kg PO BID) ($\blacktriangle$), BGJ398 (20 mg/kg PO QD) (∇), and Sorafenib (30 mg/kg PO QD) ($\diamond$) groups against Hep3b xenograft tumors in nude mice. Data were shown as mean $\pm$ SEM, $n=9$. Statistically significant difference (one-way ANOVA).

Fig. 6


7/8



A bar graph depicting the tumor weights of Hep3B-bearing nude mice. Data were shown as mean $\pm$ SEM, n=9. Statistically significant difference (one-way ANOVA), Compound 25 (100 mg/kg PO BID), Compound 25 (300 mg/kg PO BID), BGJ398 (20 mg/kg PO QD), and Sorafenib (30 mg/kg PO QD) groups vs. vehicle.

Fig. 7

8/8



A line graph depicting body weight change (%) of Hep3B-bearing nude mice following administration of vehicle and Compound 25 (100 mg/kg PO BID) ($\square$), Compound 25 (300 mg/kg PO BID) ($\blacktriangle$), BGJ398 (20 mg/kg PO QD) (∇), and Sorafenib (30 mg/kg PO QD) ($\diamond$) groups. Data were shown as mean $\pm$ SEM, $n=9$.

Fig. 8